Dr. Gregory Mt Guilcher

Dr. Gregory Mt Guilcher


Dr. Gregory Mt Guilcher , MD, FRCPC, FAAP

Pediatric Oncologist, Department of Pediatric Oncology and Blood and Marrow Transplant Alberta Children’s Hospital Associate Professor, Departments of Oncology and Paediatrics University of Calgary Faculty of Medicine
Matched Sibling Donor Hematopoietic Cell Transplantation for Sickle Disease-Past Cell, Present and Future

Dr. Guilcher is an associate professor of oncology and pediatrics at the University of Calgary. His clinical and research focus is hematopoietic cell transplantation (HCT) for non-malignant diseases. He also studies acute and late effects of oncology and BMT therapies. He serves as the Vice Chair of the Board of Directors and Clinical Operations for the Sickle Transplant Alliance for Research and is the Chair of the HCT Late Effects Taskforce for the Children’s Oncology Group. He is Program Director for Pediatric Hematology / Oncology at the University of Calgary, with a number of postdoctoral fellows at the Royal College of Physicians and Surgeons of Canada and teaches regularly in Mbarara, Uganda.

  1. HCTs, specifically as applied to sickle cell disease using a matched sibling donor
  2. Describe important measures of safety and success, including engraftment of donor blood cells and graft-versus-host disease
  3. Outline current and future directions of the practice of sibling donor HCT, including timing/eligibility, safety, and access (North American and globally)

Or, objectives:

  1. To study the history of the sibling donor HCT, including lessons learned
  2. To define current practices with a description of risks and future benefits
  3. To date, which is changing the way it works with respect to safety, access (North American and globally) and timing of HCT

 

Did you know?

The only known cure for Sickle Cell Disease is a stem cell transplant (or bone marrow transplant). Due to the significant risks involved in this procedure, including life-threatening complications, it is rarely an option for sickle cell patients.